Scarica l'app Stockscreener
70.95
6.39%
4.26
Dopo l'orario di chiusura:
69.60
-1.35
-1.90%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARWR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$66.69
Aprire:
$66.69
Volume 24 ore:
2.20M
Relative Volume:
0.87
Capitalizzazione di mercato:
$9.94B
Reddito:
$1.09B
Utile/perdita netta:
$233.57M
Rapporto P/E:
46.13
EPS:
1.5382
Flusso di cassa netto:
$327.01M
1 W Prestazione:
+10.24%
1M Prestazione:
+28.88%
6M Prestazione:
+85.78%
1 anno Prestazione:
+451.28%
Intervallo 1D:
$66.61
$70.97
Intervallo di 1 settimana:
$63.27
$70.97
Portata 52W:
$10.92
$76.76
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Nome
Arrowhead Pharmaceuticals Inc
Settore
Industria
Telefono
626-696-4702
Indirizzo
177 E COLORADO BLVD, PASADENA, CA
Compare ARWR vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
70.95 | 9.34B | 1.09B | 233.57M | 327.01M | 1.5382 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-06-05 | Iniziato | Goldman | Neutral |
| 2023-12-04 | Iniziato | BofA Securities | Buy |
| 2023-09-19 | Iniziato | Citigroup | Neutral |
| 2023-07-21 | Iniziato | TD Cowen | Outperform |
| 2023-05-12 | Downgrade | SVB Securities | Outperform → Market Perform |
| 2023-04-26 | Iniziato | SMBC Nikko | Outperform |
| 2023-04-12 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-05-11 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-01-19 | Ripresa | Goldman | Buy |
| 2021-08-06 | Reiterato | Chardan Capital Markets | Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Neutral |
| 2021-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-11-19 | Iniziato | Citigroup | Buy |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-05-08 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-04-15 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-03-24 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2020-03-17 | Iniziato | Goldman | Neutral |
| 2020-01-21 | Iniziato | SVB Leerink | Underperform |
| 2019-12-13 | Iniziato | Oppenheimer | Perform |
| 2019-11-29 | Reiterato | Chardan Capital Markets | Buy |
| 2019-11-27 | Reiterato | B. Riley FBR | Buy |
| 2019-11-25 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2019-10-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-10-22 | Reiterato | Chardan Capital Markets | Buy |
| 2019-10-03 | Iniziato | Robert W. Baird | Outperform |
| 2018-09-07 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2018-09-06 | Reiterato | Chardan Capital Markets | Buy |
| 2018-08-08 | Reiterato | Cantor Fitzgerald | Overweight |
| 2018-07-02 | Reiterato | Chardan Capital Markets | Buy |
Mostra tutto
Arrowhead Pharmaceuticals Inc Borsa (ARWR) Ultime notizie
Arrowhead Pharmaceuticals, Inc. (ARWR)’s ARO-ALK7 Enters Phase 1/2a Study - MSN
Is Arrowhead Pharmaceuticals Inc gaining market share2026 Setups & Free Long-Term Investment Growth Plans - baoquankhu1.vn
Arrowhead Pharmaceuticals Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Q3 2025 Arrowhead Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Q4 2025 Arrowhead Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Emerges as a Growth Stock with a Constructive Technical Setup - ChartMill
ARWR Stock Price, Quote & Chart | ARROWHEAD PHARMACEUTICALS IN (NASDAQ:ARWR) - ChartMill
Arrowhead Pharmaceuticals, Inc. (ARWR) Stock forecasts - Yahoo Finance UK
ViaSat, Arrowhead Pharmaceuticals, and TTM Technologies Post Over 500% Returns - Markets Mojo
H.C. Wainwright Reaffirms Their Buy Rating on Arrowhead Pharmaceuticals (ARWR) - The Globe and Mail
How (ARWR) Movements Inform Risk Allocation Models - Stock Traders Daily
Aberdeen Group plc Sells 234,498 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Arrowhead Pharmaceuticals (ARWR) Is Up 5.9% After Durable Two-Year Plozasiran Data in Severe Hypertriglyceridemia - Sahm
Arrowhead Pharmaceuticals Inc (HDP1.HM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Arrowhead Pharmaceuticals, Inc. (A2RR34.SA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Tema Etfs LLC Reduces Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals, Inc. (HDP1.F) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Arrowhead Pharmaceuticals Leads with 415.53% Return in Stock Performance - Markets Mojo
Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Forecasts - Yahoo Finance
Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Price, News, Quote & History - Yahoo! Finance Canada
Arrowhead (ARWR) FQ1 2026 revenue hits $264M as REDEMPLO approval marks commercial shift - MSN
Arrowhead Pharmaceuticals, Inc. (ARWR) Jumps 7.3% to $61.87 - AlphaStreet
Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology's 75th Annual Scientific Session and Expo - marketscreener.com
Arrowhead Plozasiran Data Supports Triglyceride Reduction And Valuation Upside Potential - Yahoo Finance
Arrowhead Pharmaceuticals (ARWR) price target increased by 17.24% to 59.24 - MSN
Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Session and Expo - Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Sp - pharmiweb.com
Trading Systems Reacting to (ARWR) Volatility - Stock Traders Daily
Arrowhead Pharmaceuticals Inc (LTS:0HI3) Bonds - GuruFocus
BofA Securities Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Cuts Target Price to $81 - moomoo.com
Stock List: Research Stocks from Around the World - GuruFocus
Vanguard amendment shows 0% holding in Arrowhead (ARWR) - Stock Titan
Arrowhead Pharma stock rating reiterated at Buy by TD Cowen - Investing.com South Africa
Analysts Conflicted on These Healthcare Names: Cibus (CBUS), Arrowhead Pharmaceuticals (ARWR) and Tarsus Pharmaceuticals (TARS) - The Globe and Mail
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Gap DownWhat's Next? - MarketBeat
BofA cuts Arrowhead Pharma stock price target on obesity prospects By Investing.com - Investing.com India
BofA cuts Arrowhead Pharma stock price target on obesity prospects - Investing.com
Sarepta Pushes Past Gene Therapy Debacle as RNA Therapies Show Early Promise - BioSpace
Arrowhead Pharmaceuticals: Transition Phase With Moderate Upside Ahead (NASDAQ:ARWR) - seekingalpha.com
Leerink reiterates Arrowhead Pharma stock rating on partner data By Investing.com - Investing.com Canada
Arrowhead Pharmaceuticals Surges as Clinical Trial Doses First Patients - StocksToTrade
Arrowhead Pharma (ARWR) Rating Reiterated as 'Buy' by HC Wainwri - gurufocus.com
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Receives "Buy" Rating from HC Wainwright - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Up 8.6%Here's What Happened - MarketBeat
Johnson & Johnson Exits 3 Biotechs but Keeps Stakes in These Rumored Acquisition Targets - Barron's
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Nordea Investment Management AB - MarketBeat
Assenagon Asset Management S.A. Purchases 304,264 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
JPMorgan Chase & Co. Grows Stake in Arrowhead Pharmaceuticals, Inc. $ARWR - marketbeat.com
Exit Recap: Whats the beta of Arrowhead Pharmaceuticals Inc stockWeekly Gains Summary & High Yield Equity Trading Tips - baoquankhu1.vn
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Hudson Bay Capital Management LP - MarketBeat
Arrowhead Pharmaceuticals Inc Azioni (ARWR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):